11/20
08:30 am
aeon
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
High
Report
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
11/18
07:20 am
aeon
AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
High
Report
AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
11/14
08:30 am
aeon
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
Medium
Report
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
10/8
12:49 pm
aeon
AEON Biopharma (NASDAQ:AEON) had its "buy" rating reaffirmed by analysts at Aegis. They now have a $7.20 price target on the stock.
Low
Report
AEON Biopharma (NASDAQ:AEON) had its "buy" rating reaffirmed by analysts at Aegis. They now have a $7.20 price target on the stock.